Executive Summary: Drug Delivery Markets, Vol I: Oral DeliveryKalorama Information Executive SummariesJanuary 1, 2007 5 Pages - SKU: KLE1467864 |
| Countries covered: Global Kalorama Information's Executive Summaries provide a comprehensive overview of the contents contained in our full-length market intelligence reports. Containing a snapshot of the overall market analysis, each Executive Summary provides a description of the scope and methodology used in the report; a summary of results including market size and market growth; a sampling of charts and graphs when available; and a brief look at the trends shaping the market. The report from which this Executive Summary is compiled is Drug Delivery Markets, Vol I: Oral Delivery, and the full study abstract is as follows: The oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the growing elderly population that requires products with a level of ease-of-use and cost benefit, it’s no surprise that the oral delivery drug market is a $35 billion industry and expected to grow as much as ten percent per year. Kalorama’s Drug Delivery Markets. Edition 2 Volume I: Oral Delivery, the first volume of Kalorama’s popular series focusing on drug delivery systems, provides the definitive break down of the market for oral delivery drug markets. The report covers both the major technologies in oral delivery (controlled-release, delayed release, pulsatile-release, taste-masked and microemulsion formulations) and the products that use these delivery technologies. In the reporting of market size and growth through 2010, Kalorama’s unique analysis also separates the value of the technology portion of the market from the active ingriedient portion of the market, allowing for a deeper understanding of the value of the market attributable to the delivery technologies themselves. This focused report provides information on the revenues for relevant companies and provides information critical to assessing the opportunities available in this market, including:
|
More Global Biopharmaceuticals Reports
Global Biosimilars Market Forecast to 2015 by
RNCOS
The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, ...
Biosimilars: Current Situation & Future Prospects, Worldwide by
JustPharmaReports.com
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with ...
World Biological Drugs Market 2012-2022 by
Visiongain
Where is the market for biological drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
Our new study ...
Global Biosimilars: A return to optimism? by
Espicom Healthcare Intelligence
Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning themselves for ...
Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition by
Kalorama Information
Several cell culture-derived biopharmaceutical drugs were launched in the US and European markets in 2010. Biopharmaceuticals (recombinant proteins, monoclonal antibody and nucleic acid-based products) represent ...
See all reports like this >>
Related Markets
Biopharmaceuticals Reports
- Research Report on Chinese Bio-pharmaceutical Industry, 2012
- Regulatory Intelligence on Biologics Recalls – Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes
- Biologics Market in Brazil
- Global Biosimilars Market Forecast to 2015
- Biosimilars: Current Situation & Future Prospects, Worldwide

